EP3596085A4 - Deuterated analogs of mk2 inhibitors and uses thereof - Google Patents

Deuterated analogs of mk2 inhibitors and uses thereof Download PDF

Info

Publication number
EP3596085A4
EP3596085A4 EP18767095.5A EP18767095A EP3596085A4 EP 3596085 A4 EP3596085 A4 EP 3596085A4 EP 18767095 A EP18767095 A EP 18767095A EP 3596085 A4 EP3596085 A4 EP 3596085A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
deuterated analogs
deuterated
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18767095.5A
Other languages
German (de)
French (fr)
Other versions
EP3596085A1 (en
Inventor
John MALONA
Sekhar S. Surapaneni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene CAR LLC
Original Assignee
Celgene CAR LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene CAR LLC filed Critical Celgene CAR LLC
Publication of EP3596085A1 publication Critical patent/EP3596085A1/en
Publication of EP3596085A4 publication Critical patent/EP3596085A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
EP18767095.5A 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof Withdrawn EP3596085A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472022P 2017-03-16 2017-03-16
PCT/US2018/022545 WO2018170201A1 (en) 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
EP3596085A1 EP3596085A1 (en) 2020-01-22
EP3596085A4 true EP3596085A4 (en) 2020-11-25

Family

ID=63523341

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18767095.5A Withdrawn EP3596085A4 (en) 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof

Country Status (4)

Country Link
US (1) US11230551B2 (en)
EP (1) EP3596085A4 (en)
JP (1) JP2020511468A (en)
WO (1) WO2018170201A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3912981A1 (en) 2014-09-17 2021-11-24 Celgene Car Llc Mk2 inhibitors and uses thereof
CN110678471B (en) 2017-03-16 2022-09-13 西建卡尔有限责任公司 MK2 inhibitors and their synthesis and intermediates
EP3596083A4 (en) 2017-03-16 2020-12-02 Celgene CAR LLC Heteroaryl compounds useful as mk2 inhibitors
JP2020511468A (en) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Deuterated analogs of MK2 inhibitors and uses thereof
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
TW202328141A (en) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 Quinolinofuran derivatives and use thereof
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372966T1 (en) 1994-03-25 2007-09-15 Isotechnika Inc IMPROVED EFFECTIVENESS OF DRUGS THROUGH DEUTERATION
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BR0317430A (en) 2002-12-20 2005-10-25 Pharmacia Corp Mitogen-activated protein kinase-activated protein kinase-2 inhibitor compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
JP2010505961A (en) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
PE20090480A1 (en) 2007-07-16 2009-05-24 Novartis Ag TETRACYCLIC LACTAM DERIVATIVES
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
US9457707B2 (en) * 2014-09-15 2016-10-04 Nissan North America, Inc. Vehicle auxiliary lamp unit
JP2020511468A (en) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Deuterated analogs of MK2 inhibitors and uses thereof
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
CN110678471B (en) 2017-03-16 2022-09-13 西建卡尔有限责任公司 MK2 inhibitors and their synthesis and intermediates
EP3596083A4 (en) * 2017-03-16 2020-12-02 Celgene CAR LLC Heteroaryl compounds useful as mk2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUMONT ET AL: "Prospects in the use of deuterated molecules as therapeutic agents", REVUE IRE, INSTITUT NATIONAL DES RADIOELEMENTS, BELGIUM, vol. 6, no. 4, January 1982 (1982-01-01), pages 2 - 10, XP009125461, ISSN: 0770-1160 *
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, January 1985 (1985-01-01), pages 1 - 40, XP009086953, ISSN: 0065-2490 *
O'DRISCOLL: "Heavyweight drugs", CHEMISTRY & INDUSTRY, SOCIETY OF CHEMICAL INDUSTRY. LONDON, GB, 9 March 2009 (2009-03-09), pages 24 - 26, XP002636700, ISSN: 0009-3068 *
TUNG R: "The Development of Deuterium-Containing Drugs", INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY, SAMEDAN LTD, GB, no. 32, March 2010 (2010-03-01), pages 24 - 26, 28, XP009148260, ISSN: 1471-7204 *

Also Published As

Publication number Publication date
JP2020511468A (en) 2020-04-16
US20210122762A1 (en) 2021-04-29
EP3596085A1 (en) 2020-01-22
WO2018170201A1 (en) 2018-09-20
US11230551B2 (en) 2022-01-25

Similar Documents

Publication Publication Date Title
EP3596085A4 (en) Deuterated analogs of mk2 inhibitors and uses thereof
EP3700527A4 (en) Papd5 inhibitors and methods of use thereof
EP3684361A4 (en) Substituted inhibitors of menin-mll and methods of use
CA193082S (en) Point of sale device
IL267869A (en) Anhydrous compositions of mtor inhibitors and methods of use
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
PL3700902T3 (en) Inhibitors of trpc6
IL290045A (en) Deuterated mk2 pathway inhibitors and methods of using the same
IL272649B (en) Ahr inhibitors and uses thereof
RS64889B1 (en) Lsd1 inhibitors and medical uses thereof
IL274504A (en) Acss2 inhibitors and methods of use thereof
EP3595658A4 (en) Forms and compositions of a mk2 inhibitor
EP3688011A4 (en) Peptide compositions and methods of use thereof
HK1251979A1 (en) Peptide compositions and methods of use
HK1246807A1 (en) Formulation of mk2 inhibitor peptides
EP3402443A4 (en) Devices and compositions and methods of use thereof
EP3353150A4 (en) Inhibitors of alk and srpk and methods of use
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
SG11202000621VA (en) Inhibitors of ror?
EP3519568A4 (en) Compositions comprising a modified glcnac-1-phosphotransferase and methods of use thereof
EP3248979A4 (en) Novel inhibitor of flt3 kinase and use thereof
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
AU2017904351A0 (en) Inhibitors of necroptosis
AU2015902765A0 (en) Novel aminopeptidase inhibitors and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201026

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/12 20060101ALI20201020BHEP

Ipc: C07D 495/14 20060101AFI20201020BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220701